A REACTION OF HEART RATE VARIABILITY SPECTRAL PARAMETERS IN THE PHARMACOLOGICAL TEST WITH MEBICAR IN HEALTHY VOLUNTEERS

On 13 conditionally healthy volunteers aged from 18 to 46 years (mean age ? 22±7,6 years) the variability of the total power (TP, ms2) of the spectrum, very low frequency (VLF, ms2), low frequency (LF, ms2) and high frequency (HF, ms2) domains of heart rate variability (HRV) in 5 minute intervals of ECG in I standard lead before and 30 minutes after oral admission of 500 mg of mebicar were evaluated. The data were processed by methods of nonparametric statistics. No significant changes in TP, VLF, LF, HF HRV after 30 minutes (maximum time declared by pharmacodynamics action) after administration of 500 mg of mebicar were noted by us. Accordingly, the effectiveness of mebicar as an adaptogen without evidence-based research cannot be postulated.